JP2017508766A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017508766A5 JP2017508766A5 JP2016558339A JP2016558339A JP2017508766A5 JP 2017508766 A5 JP2017508766 A5 JP 2017508766A5 JP 2016558339 A JP2016558339 A JP 2016558339A JP 2016558339 A JP2016558339 A JP 2016558339A JP 2017508766 A5 JP2017508766 A5 JP 2017508766A5
- Authority
- JP
- Japan
- Prior art keywords
- benzamide
- trifluoromethyl
- methyl
- phenylimidazo
- pyrazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 imidazothiazolyl Chemical group 0.000 claims 51
- 125000000217 alkyl group Chemical group 0.000 claims 27
- 125000000623 heterocyclic group Chemical group 0.000 claims 24
- 229910052739 hydrogen Inorganic materials 0.000 claims 23
- 239000001257 hydrogen Substances 0.000 claims 23
- 150000001875 compounds Chemical class 0.000 claims 18
- 150000002431 hydrogen Chemical group 0.000 claims 15
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 229910052736 halogen Inorganic materials 0.000 claims 10
- 150000002367 halogens Chemical class 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 9
- 125000003226 pyrazolyl group Chemical group 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 125000002971 oxazolyl group Chemical group 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 102000015336 Nerve Growth Factor Human genes 0.000 claims 4
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 4
- 125000002393 azetidinyl group Chemical group 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 claims 4
- 125000000842 isoxazolyl group Chemical group 0.000 claims 4
- 229940053128 nerve growth factor Drugs 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 4
- 125000000335 thiazolyl group Chemical group 0.000 claims 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 3
- 229910052801 chlorine Inorganic materials 0.000 claims 3
- 239000000460 chlorine Substances 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 239000011737 fluorine Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000016192 Demyelinating disease Diseases 0.000 claims 2
- 206010012305 Demyelination Diseases 0.000 claims 2
- 206010067601 Dysmyelination Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 2
- 101150111783 NTRK1 gene Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 2
- 125000001425 triazolyl group Chemical group 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000001305 1,2,4-triazol-3-yl group Chemical group [H]N1N=C([*])N=C1[H] 0.000 claims 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 claims 1
- 125000005330 8 membered heterocyclic group Chemical group 0.000 claims 1
- SFFADAMZFAATCL-UHFFFAOYSA-N C1(=CC=CC=C1)C=1N=C2N(C=CC=C2)C1NC(C1=CC=C(C=C1)OC(F)(F)F)=O Chemical compound C1(=CC=CC=C1)C=1N=C2N(C=CC=C2)C1NC(C1=CC=C(C=C1)OC(F)(F)F)=O SFFADAMZFAATCL-UHFFFAOYSA-N 0.000 claims 1
- RPEZXBNSHYRNCX-UHFFFAOYSA-N CC=1N=C(OC1)C=1C=C(C(=O)NC2=C(N=C3N2C=CC=C3)C3=CC=CC=C3)C=CC1C(F)(F)F Chemical compound CC=1N=C(OC1)C=1C=C(C(=O)NC2=C(N=C3N2C=CC=C3)C3=CC=CC=C3)C=CC1C(F)(F)F RPEZXBNSHYRNCX-UHFFFAOYSA-N 0.000 claims 1
- REVGBOTYDSGISF-UHFFFAOYSA-N CNC(=O)C1=CC=2N(C=C1)C(=C(N2)C2=CC=CC=C2)NC(=O)C2=CC(=C(C=C2)C(F)(F)F)C2=NN(C=C2)C Chemical compound CNC(=O)C1=CC=2N(C=C1)C(=C(N2)C2=CC=CC=C2)NC(=O)C2=CC(=C(C=C2)C(F)(F)F)C2=NN(C=C2)C REVGBOTYDSGISF-UHFFFAOYSA-N 0.000 claims 1
- QPVLLQUDWADQBA-UHFFFAOYSA-N FC1=C(C=C(C(Cl)=C1)C1=NC=CC=N1)C(=O)NC1=C(N=C2C=CC=CN12)C1=CC=CC=C1 Chemical compound FC1=C(C=C(C(Cl)=C1)C1=NC=CC=N1)C(=O)NC1=C(N=C2C=CC=CN12)C1=CC=CC=C1 QPVLLQUDWADQBA-UHFFFAOYSA-N 0.000 claims 1
- HHMKUHNKLXBXGU-UHFFFAOYSA-N FC1=C(C=CC(=C1)C(F)(F)F)C(=O)NC1=C(N=C2C=CC=CN12)C1=CC=CC=C1 Chemical compound FC1=C(C=CC(=C1)C(F)(F)F)C(=O)NC1=C(N=C2C=CC=CN12)C1=CC=CC=C1 HHMKUHNKLXBXGU-UHFFFAOYSA-N 0.000 claims 1
- UFCQAORTJKBJIM-UHFFFAOYSA-N FC1=C(C=CC(=C1)C(F)(F)F)C(=O)NC1=C(N=C2SC=CN12)C1=CC=CC=C1 Chemical compound FC1=C(C=CC(=C1)C(F)(F)F)C(=O)NC1=C(N=C2SC=CN12)C1=CC=CC=C1 UFCQAORTJKBJIM-UHFFFAOYSA-N 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000001594 aberrant effect Effects 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229910017464 nitrogen compound Inorganic materials 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2014/074143 | 2014-03-26 | ||
| PCT/CN2014/074143 WO2015143652A1 (en) | 2014-03-26 | 2014-03-26 | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
| PCT/US2015/022004 WO2015148373A2 (en) | 2014-03-26 | 2015-03-23 | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017508766A JP2017508766A (ja) | 2017-03-30 |
| JP2017508766A5 true JP2017508766A5 (cg-RX-API-DMAC7.html) | 2018-05-10 |
Family
ID=54193893
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016558347A Pending JP2017512786A (ja) | 2014-03-26 | 2015-03-23 | ＴｒｋＡキナーゼ阻害薬、その組成物および方法 |
| JP2016558339A Pending JP2017508766A (ja) | 2014-03-26 | 2015-03-23 | ＴｒｋＡキナーゼ阻害薬、その組成物および方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016558347A Pending JP2017512786A (ja) | 2014-03-26 | 2015-03-23 | ＴｒｋＡキナーゼ阻害薬、その組成物および方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9862716B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3122345B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2017512786A (cg-RX-API-DMAC7.html) |
| KR (2) | KR20160132114A (cg-RX-API-DMAC7.html) |
| CN (2) | CN106456581A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2015236438A1 (cg-RX-API-DMAC7.html) |
| CA (2) | CA2942817A1 (cg-RX-API-DMAC7.html) |
| MX (2) | MX2016012481A (cg-RX-API-DMAC7.html) |
| RU (2) | RU2016141647A (cg-RX-API-DMAC7.html) |
| WO (3) | WO2015143652A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105418615B (zh) * | 2015-12-09 | 2018-02-02 | 北京工业大学 | 苯甲酰胺衍生物及制备和应用 |
| US11701345B2 (en) | 2017-06-19 | 2023-07-18 | University Of Maryland, Baltimore | Car activator agents for cyclophosphamide-based treatments of cancer |
| EP3692052A4 (en) | 2017-10-04 | 2021-03-17 | Dana Farber Cancer Institute, Inc. | INHIBITION BY SMALL MOLECULES OF THE TRANSCRIPTION FACTOR SALL4 AND ITS USES |
| KR20190043437A (ko) | 2017-10-18 | 2019-04-26 | 씨제이헬스케어 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
| ES2908773T3 (es) * | 2017-12-15 | 2022-05-03 | Pyramid Biosciences Inc | Derivados de 5-(2-(2,5-difluorofenil)pirrolidin-1-il)-3-(1H-pirazol-1-il)pirazolo[1,5-a]pirimidina y compuestos relacionados como inhibidores de Trk quinasa para el tratamiento del cáncer |
| IL298250B2 (en) | 2018-04-12 | 2025-01-01 | Bayer Ag | N-(cyclopropylmethyl)-5-(methylsulfonyl)-N-{1-[1-(pyrimidin-2-yl)-H1-1, 2, 4-triazol-5-yl]ethyl}benzamide derivatives and pyridine-carboxamide derivatives are compatible as pesticides |
| KR102129114B1 (ko) * | 2018-07-26 | 2020-07-02 | 주식회사 온코파마텍 | TrkA 저해 활성을 갖는 화합물 및 이를 유효성분으로 함유하는 통증의 예방 또는 치료용 약학적 조성물 |
| EP3841098A4 (en) * | 2018-08-22 | 2022-05-04 | Cullgen (Shanghai), Inc. | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHOD OF USE |
| US11969472B2 (en) | 2018-08-22 | 2024-04-30 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use |
| KR102195348B1 (ko) | 2018-11-15 | 2020-12-24 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물 |
| CN111269233A (zh) * | 2018-12-05 | 2020-06-12 | 上海轶诺药业有限公司 | 一类咪唑并芳环类化合物的制备和应用 |
| CN114364798A (zh) | 2019-03-21 | 2022-04-15 | 欧恩科斯欧公司 | 用于治疗癌症的Dbait分子与激酶抑制剂的组合 |
| UY38911A (es) | 2019-10-09 | 2021-05-31 | Bayer Ag | Compuestos de heteroarilo-triazol como pesticidas, formulaciones, usos y métodos de uso de los mismos |
| US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| TW202134226A (zh) | 2019-11-18 | 2021-09-16 | 德商拜耳廠股份有限公司 | 作為殺蟲劑之新穎雜芳基-三唑化合物 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN115697989B (zh) | 2020-02-26 | 2025-03-18 | 上海睿跃生物科技有限公司 | 原肌球蛋白受体激酶(trk)降解化合物和使用方法 |
| WO2021197467A1 (zh) * | 2020-04-02 | 2021-10-07 | 上海华汇拓医药科技有限公司 | 多靶点的抗肿瘤化合物及其制备方法和应用 |
| TW202210467A (zh) * | 2020-05-28 | 2022-03-16 | 美商美國禮來大藥廠 | TrkA抑制劑 |
| CN113666862B (zh) * | 2021-08-18 | 2024-05-31 | 山东大学 | 一种通过镍催化不对称硝化反应制备手性3-硝基吲哚类化合物的方法 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB599834A (en) * | 1943-04-08 | 1948-03-22 | Francolor Sa | Improvements in or relating to the manufacture of azodyestuffs |
| CA2169719C (en) * | 1994-06-21 | 2002-04-16 | Yasuo Shoji | Pyrazolo[1,5-a]pyrimidine derivative |
| IT1306704B1 (it) | 1999-05-26 | 2001-10-02 | Sirs Societa Italiana Per La R | Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf. |
| DE19946322A1 (de) | 1999-09-28 | 2001-03-29 | Bayer Ag | Verfahren zur Konditionierung von Ionenaustauscherharzen |
| FR2807660A1 (fr) | 2000-04-13 | 2001-10-19 | Warner Lambert Co | Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques |
| WO2001081345A1 (en) * | 2000-04-20 | 2001-11-01 | Mitsubishi Pharma Corporation | Aromatic amide compounds |
| US20050009876A1 (en) * | 2000-07-31 | 2005-01-13 | Bhagwat Shripad S. | Indazole compounds, compositions thereof and methods of treatment therewith |
| US6897231B2 (en) * | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| KR100713137B1 (ko) * | 2001-06-28 | 2007-05-02 | 동화약품공업주식회사 | 신규의 2,4-디플루오로벤즈아미드 유도체 |
| ATE495741T1 (de) * | 2001-09-26 | 2011-02-15 | Pfizer Italia Srl | Aminoindazolderivate mit kinaseinhibierender wirkung, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen |
| US20030144518A1 (en) * | 2001-12-07 | 2003-07-31 | The Procter & Gamble Company | Process for preparing 3-acylamino-imidazo[1,2-a]pyridines |
| JP2003231687A (ja) * | 2002-02-04 | 2003-08-19 | Japan Tobacco Inc | ピラゾリル縮合環化合物及びその医薬用途 |
| WO2003068773A1 (en) * | 2002-02-12 | 2003-08-21 | Glaxo Group Limited | Pyrazolopyridine derivatives |
| US7098334B2 (en) * | 2002-03-25 | 2006-08-29 | Industrial Research Limited | 4-amino-5H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases |
| EP1388341A1 (en) | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| UA80447C2 (en) | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
| SI2263692T1 (sl) | 2002-12-24 | 2020-10-30 | Rinat Neuroscience Corp. | Anti-NGF protitelesa in postopki, v katerih se le-ta uporabljajo |
| PL1618092T3 (pl) | 2003-05-01 | 2011-02-28 | Bristol Myers Squibb Co | Związki amidopirazolowe z podstawnikami arylowymi jako inhibitory kinazy |
| CN102358903B (zh) | 2003-07-15 | 2017-04-26 | 安姆根有限公司 | 作为选择性ngf途径抑制剂的人抗ngf中和抗体 |
| WO2005030128A2 (en) | 2003-09-23 | 2005-04-07 | Merck & Co., Inc. | Pyrazole modulators of metabotropic glutamate receptors |
| US20050143384A1 (en) | 2003-10-30 | 2005-06-30 | Eric Sartori | Amide thiadiazole inhibitors of plasminogen activator inhibitor-1 |
| ITRM20030601A1 (it) | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
| JP2007526324A (ja) * | 2004-03-02 | 2007-09-13 | スミスクライン・ビーチャム・コーポレイション | Ａｋｔ活性のある阻害剤 |
| CN101010315A (zh) | 2004-04-30 | 2007-08-01 | 拜耳制药公司 | 用于治疗癌症的取代的吡唑基脲衍生物 |
| PL1853602T3 (pl) | 2005-02-16 | 2010-11-30 | Astrazeneca Ab | Związki chemiczne |
| EP1877057A1 (en) | 2005-04-27 | 2008-01-16 | AstraZeneca AB | Use of pyrazolyl-pyrimidine derivatives in the treatment of pain |
| JP2008540622A (ja) | 2005-05-16 | 2008-11-20 | アストラゼネカ アクチボラグ | 化合物 |
| ITRM20050290A1 (it) | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
| ITRM20050332A1 (it) | 2005-06-24 | 2006-12-25 | Lay Line Genomics Spa | Uso di molecole in grado di bloccare l'attivita' di trka per potenziare gli effetti di analgesici oppiacei sul dolore. |
| AU2006270322A1 (en) * | 2005-07-14 | 2007-01-25 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| JP2009502734A (ja) | 2005-07-29 | 2009-01-29 | アステラス製薬株式会社 | Ｌｃｋ阻害剤としての縮合複素環 |
| DE102005042742A1 (de) | 2005-09-02 | 2007-03-08 | Schering Ag | Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
| WO2007042321A2 (en) | 2005-10-13 | 2007-04-19 | Devgen N.V. | Kinase inhibitors |
| EP1959944A1 (en) | 2005-12-15 | 2008-08-27 | Shionogi Co., Ltd. | A pharmaceutical composition comprising an amide derivative |
| BRPI0712795A2 (pt) | 2006-07-07 | 2012-09-04 | Boehringer Ingelheim Int | derivados de heteroarila substituìdos com fenila e uso dos mesmos como agentes antitumorais |
| EP2058309A4 (en) * | 2006-08-04 | 2010-12-22 | Takeda Pharmaceutical | CONDENSED HETEROCYCLIC COMPOUND |
| BRPI0718266A2 (pt) | 2006-10-30 | 2014-01-07 | Novartis Ag | Compostos heterocíclicos como agentes anti-inflamatórios. |
| KR101506750B1 (ko) | 2007-04-06 | 2015-03-27 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 고나도트로핀-방출 호르몬 수용체 길항제 및 그와 관련된 방법 |
| GB0708188D0 (en) * | 2007-04-27 | 2007-06-06 | Merck Sharp & Dohme | Therapeutic compounds |
| WO2008154241A1 (en) * | 2007-06-08 | 2008-12-18 | Abbott Laboratories | 5-heteroaryl substituted indazoles as kinase inhibitors |
| PE20090837A1 (es) | 2007-07-02 | 2009-07-24 | Boehringer Ingelheim Int | Nuevos compuestos quimicos |
| EP2176249A2 (en) | 2007-07-02 | 2010-04-21 | Boehringer Ingelheim International GmbH | New chemical compounds |
| NZ583450A (en) * | 2007-07-20 | 2012-05-25 | Nerviano Medical Sciences Srl | Substituted indazole derivatives active as kinase inhibitors |
| PL2197849T3 (pl) | 2007-10-09 | 2013-05-31 | Merck Patent Gmbh | Pochodne n-(pirazolo-3-ylo)-benzamidowe jako aktywatory glukokinazowe |
| CN102224153B (zh) | 2008-09-22 | 2014-04-30 | 阵列生物制药公司 | 作为trk激酶抑制剂的取代的咪唑并[1，2-b]哒嗪化合物 |
| US8703962B2 (en) | 2008-10-24 | 2014-04-22 | Purdue Pharma L.P. | Monocyclic compounds and their use as TRPV1 ligands |
| KR101048448B1 (ko) * | 2008-11-21 | 2011-07-11 | 한국화학연구원 | 신규 피라졸로[4,3-ｂ]피리딘 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물 |
| KR101805754B1 (ko) | 2008-12-08 | 2017-12-07 | 먼디파머 인터내셔널 코포레이션 리미티드 | 단백질 수용체 티로신 키나아제 억제제의 조성물 |
| US20120065247A1 (en) | 2009-03-27 | 2012-03-15 | Discoverybiomed, Inc. | Modulating ires-mediated translation |
| EP2459184A1 (en) * | 2009-07-31 | 2012-06-06 | The Brigham and Women's Hospital, Inc. | Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses |
| EP3257854A1 (en) * | 2009-11-05 | 2017-12-20 | University of Notre Dame du Lac | Imidazo[1,2-a]pyridine compounds, synthesis thereof, and methods of using same |
| NZ604831A (en) | 2010-07-02 | 2014-12-24 | Gilead Sciences Inc | Apoptosis signal-regulating kinase inhibitors |
| BR112013002879A2 (pt) * | 2010-08-05 | 2016-05-31 | Amgen Inc | compostos de benizmidazol e azabenzimidazol que inibem a quinase de linfoma anaplásico |
| BR112013005070B1 (pt) | 2010-09-01 | 2018-04-03 | Bayer Intellectual Property Gmbh | Compostos n-(tetrazol-5-il)- e n-(triazol-5-il) arilcarboxamidas, composição herbicida, seus usos como herbicidas e método para controlar plantas indesejadas |
| KR20130141500A (ko) * | 2010-09-29 | 2013-12-26 | 크리스탈지노믹스(주) | 단백질 키나제 억제 활성을 갖는 신규한 아미노퀴나졸린 화합물 |
| WO2012100223A1 (en) | 2011-01-21 | 2012-07-26 | John Irwin | Synthetic lethal targeting of glucose transport |
| MX2013009067A (es) | 2011-02-09 | 2013-10-01 | Syngenta Participations Ag | Compuestos insecticidas. |
| BR112013029201B1 (pt) | 2011-05-13 | 2022-08-09 | Array Biopharma Inc | Compostos de pirrolidinil ureia e pirrolidinil tioureia, seu processo de preparação, seu uso e composições farmacêuticas |
| CN102796103A (zh) | 2011-05-23 | 2012-11-28 | 南京英派药业有限公司 | 6-（芳基甲酰）咪唑并[1,2-a]嘧啶和6-（芳基甲酰）[1,2,4]三唑并[4,3-a]嘧啶作为Hedgehog抑制剂及其应用 |
| SG194107A1 (en) | 2011-05-23 | 2013-11-29 | Merck Patent Gmbh | Thiazole derivatives |
| US9102673B2 (en) * | 2011-07-12 | 2015-08-11 | Merck Sharp & Dohme Corp. | Substituted pyrrolo[3,2-c]pyridines as TrkA kinase inhibitors |
| BR112014011465A2 (pt) * | 2011-11-14 | 2017-05-09 | Tesaro Inc | modulação de determinadas quinases de tirosina |
| CN104114553B (zh) * | 2011-12-12 | 2017-03-01 | 雷迪博士实验室有限公司 | 作为原肌球蛋白受体激酶(Trk)抑制剂的取代的吡唑并[1,5‑a]吡啶 |
| EP2689778A1 (en) * | 2012-07-27 | 2014-01-29 | Pierre Fabre Medicament | Derivatives of azaindoles or diazaindoles for treating pain |
| EP2689779A1 (en) | 2012-07-27 | 2014-01-29 | Pierre Fabre Medicament | Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk |
| TWI652014B (zh) * | 2013-09-13 | 2019-03-01 | 美商艾佛艾姆希公司 | 雜環取代之雙環唑殺蟲劑 |
-
2014
- 2014-03-26 WO PCT/CN2014/074143 patent/WO2015143652A1/en not_active Ceased
-
2015
- 2015-03-23 KR KR1020167029495A patent/KR20160132114A/ko not_active Withdrawn
- 2015-03-23 AU AU2015236438A patent/AU2015236438A1/en not_active Abandoned
- 2015-03-23 US US15/129,206 patent/US9862716B2/en active Active
- 2015-03-23 AU AU2015236363A patent/AU2015236363A1/en not_active Abandoned
- 2015-03-23 EP EP15769224.5A patent/EP3122345B1/en active Active
- 2015-03-23 MX MX2016012481A patent/MX2016012481A/es unknown
- 2015-03-23 JP JP2016558347A patent/JP2017512786A/ja active Pending
- 2015-03-23 US US15/128,793 patent/US9862707B2/en active Active
- 2015-03-23 CN CN201580027483.7A patent/CN106456581A/zh active Pending
- 2015-03-23 MX MX2016012483A patent/MX2016012483A/es unknown
- 2015-03-23 WO PCT/US2015/021952 patent/WO2015148354A2/en not_active Ceased
- 2015-03-23 JP JP2016558339A patent/JP2017508766A/ja active Pending
- 2015-03-23 RU RU2016141647A patent/RU2016141647A/ru not_active Application Discontinuation
- 2015-03-23 KR KR1020167029497A patent/KR20160131119A/ko not_active Withdrawn
- 2015-03-23 EP EP15769051.2A patent/EP3122344B1/en active Active
- 2015-03-23 WO PCT/US2015/022004 patent/WO2015148373A2/en not_active Ceased
- 2015-03-23 CA CA2942817A patent/CA2942817A1/en not_active Abandoned
- 2015-03-23 RU RU2016141645A patent/RU2016141645A/ru not_active Application Discontinuation
- 2015-03-23 CA CA2942957A patent/CA2942957A1/en not_active Abandoned
- 2015-03-23 CN CN201580027484.1A patent/CN106456582A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017508766A5 (cg-RX-API-DMAC7.html) | ||
| RU2016141645A (ru) | ИНГИБИТОРЫ TrkA КИНАЗЫ, ОСНОВАННЫЕ НА НИХ КОМПОЗИЦИИ И СПОСОБЫ | |
| JP2017512786A5 (cg-RX-API-DMAC7.html) | ||
| JP2017512794A5 (cg-RX-API-DMAC7.html) | ||
| AU2011242569B2 (en) | Certain amino-pyridazines, compositions thereof, and methods of their use | |
| RU2016141646A (ru) | Ингибиторы trka киназы, основанные на них композиции и способы | |
| JP2020521730A5 (cg-RX-API-DMAC7.html) | ||
| ES2620657T3 (es) | Derivado de triazol o sal del mismo | |
| JP2010533158A5 (cg-RX-API-DMAC7.html) | ||
| RU2017105296A (ru) | Новые соединения | |
| RU2017121044A (ru) | Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы | |
| JP2012532931A5 (cg-RX-API-DMAC7.html) | ||
| RU2008116575A (ru) | Производные 3-циклил-2-(4-сульфамоилфенил)-n-циклилпропионамида, применимые для лечения нарушенной переносимости глюкозы и диабета | |
| JP2008523041A5 (cg-RX-API-DMAC7.html) | ||
| RU2017125520A (ru) | Соединения, ингибирующие parg | |
| JP2017538750A5 (cg-RX-API-DMAC7.html) | ||
| EP4514790A1 (en) | Compounds for inhibiting kif18a | |
| EP2807157A1 (en) | 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors | |
| JP2017537948A5 (cg-RX-API-DMAC7.html) | ||
| JP2020527560A5 (cg-RX-API-DMAC7.html) | ||
| AU2012345557A1 (en) | Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease | |
| JP2007519694A5 (cg-RX-API-DMAC7.html) | ||
| JP2016534124A5 (cg-RX-API-DMAC7.html) | ||
| JP2017523223A5 (cg-RX-API-DMAC7.html) | ||
| JP2020502230A5 (cg-RX-API-DMAC7.html) |